Fulfilling the promise of precision medicine through quality and innovation

by individualizing cancer treatments and pioneering a better molecular understanding of cancer

Caris Life Sciences believes personalized and precise information can change the face of cancer care

Our Platforms

To fulfill the promise of precision medicine and to facilitate a deeper understanding of the biology of cancer and other complex diseases, Caris Life Sciences® has developed a patented and proprietary biotargeting system. ADAPT Biotargeting System measures millions of molecular interactions within complex biological systems for drug target identification, therapeutic discovery and development, companion diagnostics, blood-based cancer screening, and biomarker identification.

Caris Life Sciences also pioneered the first molecular testing offering to help physicians make more informed treatment decisions. As the industry leader, our comprehensive tumor profiling approach assesses DNA, RNA and Proteins to reveal the molecular drivers of cancer that serves as a blueprint to enable the delivery of personalized medicine.

Identifying novel molecular targets for drug development and diagnostics

Learn More

Molecular testing to guide optimum treatment selection by physicians

Learn More
service image

Molecular Profiling & Precision Medicine Innovation Webinars

Educational Webinar Series from Caris Life Sciences. Join us every Tuesday and Friday to explore and discuss the latest innovations and offerings in molecular science with Caris medical and scientific staff. Thirty minute live webinars every Tuesday at 3PM CT and every Friday at 10AM CT. See the schedule of topics.

service image

Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care

Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic components of a patient’s cancer. Caris will begin offering Ambry’s 67-gene CancerNext-Expanded panel to evaluate the hereditary risks for cancer.

service image

FDA Breakthrough Device Designation

Caris received U.S. FDA Breakthrough Device designation for MI Transcriptome companion diagnostic (CDx) test. Designed to detect gene fusions in solid tumors, the test is intended to assist clinicians in identifying patients who may benefit from treatment with specific targeted therapies.

Since 2008 - A leader in diagnostic, prognostic and theranostic medicine
More than 218,000 clinical cases and counting


When the next step in treatment is uncertain, Caris Life Sciences illuminates a clearer path to personalized treatment selection with our industry leading, patented and proprietary offering, Caris Molecular Intelligence. Also, learn how we are pioneering a new era in drug development and advanced diagnostics with our proprietary ADAPT Biotargeting System.

Enable Precision Medicine

It's time to treat cancer smarter


Although cancer treatments have significantly advanced over the years, current cancer care options are failing too many patients. It's time to treat cancer smarter. An analysis of your cancer with Caris Molecular Intelligence may identify biomarkers that could lead towards a better understanding of what is causing your cancer to grow and inform personalized treatments to specifically target your cancer.

Visit Patients Page

Latest News and Social Media Posts

As a leader in precision healthcare and informatics, Caris Life Sciences is continually exploring new technologies and partnering with other trailblazers in the field. We're always excited to share our most recent accomplishments and discoveries.

Visit News PortalSocial Media Posts